Current role of metaiodobenzylguanidine in the diagnosis of pheochromocytoma and medullary thyroid cancer

Seminars in Nuclear Medicine

Volumn 41, Issue 5, 2011, Pages 364-368

  Ilias, Ioannis ^a   Divgi, Chaitanya ^b   Pacak, Karel ^c  

^a E Venizelou Hospital   (Greece)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; 6 FLUORODOPA F 18; 6 FLUORODOPAMINE F 18; FLUORODEOXYGLUCOSE F 18; PENTETREOTIDE; POTASSIUM IODIDE; POTASSIUM PERCHLORATE;

CELL MEMBRANE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG HALF LIFE; GAMMA RADIATION; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PARAGANGLIOMA; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; RADIATION ABSORPTION; RADIATION DOSE; REVIEW; SENSITIVITY AND SPECIFICITY; THYROID MEDULLARY CARCINOMA;

3-IODOBENZYLGUANIDINE; ADRENAL GLAND NEOPLASMS; ANIMALS; BIOLOGICAL TRANSPORT; HUMANS; PHEOCHROMOCYTOMA; THYROID NEOPLASMS;

EID: 79960927665     PISSN: 00012998     EISSN: 15584623     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2011.03.003     Document Type: Review

References (47)

1. Lack EE: Adrenal cortical nodules and tumor-like lesions, in Tumors of the Adrenal Gland and Extra-adrenal Paraganglia. Washington, DC, Armed Forces Institute of Pathology, 1997
2. Kimura N, Cappela C, De Krijger RR, et al: Extra-adrenal sympathetic paraganglioma: superior and inferior paraaortic, in DeLellis RA, Lloyd RV, Heitz PU, et al (eds): Pathology and Genetics of Tumours of Endocrine Organs: WHO Classification of Tumours (vol 8). Lyon, France, IARC Press, 2004
3. McNicol AM, Young WF Jr, Kawashima A, et al: Benign phaeochromocytoma, in DeLellis RA, Lloyd RV, Heitz PU, et al (eds): Pathology and Genetics of Tumours of Endocrine Organs: WHO Classification of Tumours (vol 8). Lyon, France, IARC Press, 2004
4. Thompson LDR, Young WF Jr, Kawashima A, et al: Malignant adrenal phaeochromocytoma, in DeLellis RA, Lloyd RV, Heitz PU, et al (eds): Pathology and Genetics of Tumours of Endocrine Organs: WHO Classification of Tumours (vol 8). Lyon, France, IARC Press, 2004
5. Ilias I, Pacak K: A clinical overview of pheochromocytomas/paragangliomas and carcinoid tumors. Nucl Med Biol 35(Suppl 1):S27-S34, 2008
6. Lack EE: Extra-adrenal paragangliomas of the sympathoadrenal neuroendocrine system, in Tumors of the Adrenal Gland and Extra-adrenal Paraganglia. Washington, DC, Armed Forces Institute of Pathology, 1997
7. Kimura N, Chetty R, Cappela C, et al: Extra-adrenal paraganglioma: carotid body, jugulotympanic, vagal, laryngeal, aortico-pulmonary, in DeLellis RA, Lloyd RV, Heitz PU, et al (eds): Pathology and Genetics of Tumours of Endocrine Organs: WHO Classification of Tumours (vol 8). Lyon, France, IARC Press, 2004
8. Jacques AE, Sahdev A, Sandrasagara M, et al: Adrenal phaeochromocytoma: correlation of MRI appearances with histology and function. Eur Radiol 18:2885-2892, 2008
9. Elsayes KM, Menias CO, Siegel CL, et al: Magnetic resonance characterization of pheochromocytomas in the abdomen and pelvis: imaging findings in 18 surgically proven cases. J Comput Assist Tomogr 34:548- 553, 2010
10. Mittendorf EA, Evans DB, Lee JE, et al: Pheochromocytoma: advances in genetics, diagnosis, localization, and treatment. Hematol/Oncol Clin North Am 21:509-525, 2007
11. Go AS: Refining probability: an introduction to the use of diagnostic tests, in Friedland DJ (ed): Evidence-Based Medicine. New York, NY, McGraw-Hill, 1998
12. Ilias I, Pacak K: Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. J Clin Endocrinol Metab 89:479-491, 2004 (Pubitemid 38269845)
13. Shulkin BL, Ilias I, Sisson JC, et al: Current trends in functional imaging of pheochromocytomas and paragangliomas. Ann N Y Acad Sci 1073:374-382, 2006 (Pubitemid 44912032)
14. Swanson DP, Carey JE, Brown LE, et al: Human absorbed dose calculations for iodine-131 and iodine-123 labeled meta-iodobenzylguanidine (mIBG): a potential myocardial and adrenal medulla imaging agent. Presented at the 3rd International Radiopharmaceutical Dosimetry Symposium, Rockville, MD, 1981
15. Lynn MD, Shapiro B, Sisson JC, et al: Portrayal of pheochromocytoma and normal human adrenal medulla by m-[123I] iodobenzylguanidine: concise communication. J Nucl Med 25:436-440, 1984 (Pubitemid 14131966)
16. Shapiro B, Gross MD: Radiochemistry, biochemistry, and kinetics of 131I-metaiodobenzylguanidine (MIBG) and 123I-MIBG: clinical implications of the use of 123I-MIBG. Med Pediatr Oncol 15:170-177, 1987 (Pubitemid 18025972)
17. Bombardieri E, Giammarile F, Aktolun C, et al: 131I/123I- metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumor imaging. Eur J Nucl Med Mol Imaging 37:2436-2446, 2010
18. Sisson JC, Shulkin BL: Nuclear medicine imaging of pheochromocytoma and neuroblastoma. Q J Nucl Med 43:217-223, 1999 (Pubitemid 29500578)
19. Nielsen JT, Nielsen BV, Rehling M: Location of adrenal medullary pheochromocytoma by I-123-metaiodobenzylguanidine SPECT. Clin Nucl Med 21:695-699, 1996 (Pubitemid 26303723)
20. Van Der Horst-Schrivers AN, Jager PL, Boezen HM, et al: Iodine-123 meta-iodobenzylguanidine scintigraphy in localising phaeochromocytomas: experience and meta-analysis. Anticancer Res 26:1599-1604, 2006
21. Bhatia KS, Ismail MM, Sahdev A, et al: 123I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation. Clin Endocrinol (Oxf) 69:181-188, 2008 (Pubitemid 352009037)
22. Wiseman GA, Pacak K, O'Dorisio MS, et al: Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial. J Nucl Med 50:1448-1454, 2009
23. Milardovic R, Corssmit EP, Stokkel M: Value of 123I-MIBG scintigraphy in paraganglioma. Neuroendocrinology 91:94-100, 2010
24. Jacobson AF, Deng H, Lombard J, et al: 123I-meta-iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysis. J Clin Endocrinol Metab 95:2596-2606, 2010
25. Lev I, Kelekar G, Waxman A, et al: Clinical use and utility of metaiodobenzylguanidine scintigraphy in pheochromocytoma diagnosis. Endocr Pract 16:398-407, 2010
26. Ilias I, Yu J, Carrasquillo JA, et al: Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]- metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab 88:4083-4087, 2003 (Pubitemid 37153702)
27. Ilias I, Chen CC, Carrasquillo JA, et al: Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma. J Nucl Med 49:1613-1619, 2008
28. Fliedner SM, Lehnert H, Pacak K: Metastatic paraganglioma. Semin Oncol 37:627-637, 2010
29. Fottner C, Helisch A, Anlauf M, et al: 6-18F-fluoro-L- dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl- guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression. J Clin Endocrinol Metab 95:2800-2810, 2010
30. Timmers HJ, Kozupa A, Chen CC, et al: Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol 25:2262-2269, 2007 (Pubitemid 46954653)
31. Koopmans KP, Jager PL, Kema IP, et al: 111In-octreotide is superior to 123I-metaiodobenzylguanidine for scintigraphic detection of head and neck paragangliomas. J Nucl Med 49:1232-1237, 2008
32. Timmers HJ, Chen CC, Carrasquillo JA, et al: Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 94:4757-4767, 2009
33. Coleman RE, Stubbs JB, Barrett JA, et al: Radiation dosimetry, pharmacokinetics, and safety of ultratrace iobenguane I-131 in patients with malignant pheochromocytoma/paraganglioma or metastatic carcinoid. Cancer Biother Radiopharm 24:469-475, 2009
34. Barrett JA, Joyal JL, Hillier SM, et al: Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution. Cancer Biother Radiopharm 25:299-308, 2010
35. Havekes B, King K, Lai EW, et al: New imaging approaches to phaeochromocytomas and paragangliomas. Clin Endocrinol (Oxf) 72:137-145, 2010
36. Ilias I, Pacak K: Diagnosis, localization and treatment of pheochromocytoma in MEN 2 syndrome. Endocr Regul 43:89-93, 2009
37. Meyer-Rochow GY, Schembri GP, Benn DE, et al: The utility of metaiodobenzylguanidine single photon emission computed tomography/computed tomography (MIBG SPECT/CT) for the diagnosis of pheochromocytoma. Ann Surg Oncol 17:392-400, 2010
38. Hicks RJ: Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy. Cancer Imaging 10:S83-S91, 2010
39. Giammarile F, Chiti A, Lassmann M, et al: EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. Eur J Nucl Med Mol Imaging 35:1039-1047, 2008
40. Scholz T, Eisenhofer G, Pacak K, et al: Clinical review: current treatment of malignant pheochromocytoma. J Clin Endocrinol Metab 92:1217-1225, 2007 (Pubitemid 46556388)
41. Martiniova L, Perera SM, Brouwers FM, et al: Increased uptake of [123I]meta-iodobenzylguanidine, [18F]fluorodopamine, and [3H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors. Endocr Relat Cancer 18:143-157, 2011
42. Nyström E, Berg GEB, Jansson SKG, et al: Thyroid cancer, in Thyroid Disease in Adults. Berlin, Springer-Verlag, 2011
43. Endo K, Shiomi K, Kasagi K, et al: Imaging of medullary thyroid cancer with 131I-MIBG. Lancet 2:233, 1984 (Pubitemid 14094991)
44. Baulieu JL, Guilloteau D, Delisle MJ, et al: Radioiodinated meta-iodobenzylguanidine uptake in medullary thyroid cancer: a French cooperative study. Cancer 60:2189-2194, 1987 (Pubitemid 17153481)
45. Gao Z, Biersack HJ, Ezziddin S, et al: The role of combined imaging in metastatic medullary thyroid carcinoma: 111In-DTPA-octreotide and 131I/123I-MIBG as predictors for radionuclide therapy. J Cancer Res Clin Oncol 130:649-656, 2004 (Pubitemid 39506378)
46. Szakáll SJ, Ésik O, Bajzik G, et al: 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med 43:66-71, 2002 (Pubitemid 34101190)
47. Rufini V, Castaldi P, Treglia G, et al: Nuclear medicine procedures in the diagnosis and therapy of medullary thyroid carcinoma. Biomed Pharmacother 62:139-146, 2008 (Pubitemid 351381932)